Exozymes Inc (EXOZ)

$DNA if all the SynBio fans want the real deal - an actual company and technology that can scale and deliver on the promise - check out $EXOZ

$EXOZ In a recent episode of The Big Skinny - the SportsCenter of Financial News - Fox Business contributor @LouBasenese, stated: "eXoZymes is a new way to create chemicals. It's like the BASF of the 2026 [...] We don't make a lot of the products you buy. We make a lot of the products you buy better." Full episode available here: https://na2.hubs.ly/H03Ys2R0 #exozymes #exozyme #enzymes #enzyme #biomanufacturing $EXOZ

$EXOZ Current Stock Price: $9.00

eXoZymes (Nasdaq: $EXOZ) has launched a redesigned corporate website and updated visual identity, reflecting the company’s refined strategic focus on pharmaceutical and high-value nutraceutical markets. eXoZymes Inc. is a B2i Digital Featured Company. See their full profile at https://b2idigital.com/exozymes-1. The rebrand follows the company’s previously communicated decision to sharpen its commercial scope toward sectors where management believes its AI-enhanced, cell-free exozyme platform can provide differentiated capabilities. eXoZymes is concentrating resources on markets characterized by defined regulatory pathways, technical barriers to entry, IP defensibility, and durable demand. The updated website and color scheme, commonly associated with biotech and pharma, are designed to align the company’s external presentation with this direction. CEO Michael Heltzen outlined the logic behind the shift: “Our strategy is built around disciplined focus and platform leverage. We are concentrating our technology and business development efforts on highly valuable pharmaceutical and nutraceutical markets - segments that we believe are defined by no or low current access, attractive margin profiles, strong intellectual property protection, meaningful technical barriers to entry, and long-term commercial durability.” Read the full announcement here: https://exozymes.com/blog/refreshed-brand-2026 eXoZymes is a Los Angeles, California-based biotechnology company pioneering cell-free biomanufacturing through AI-engineered enzymes that transform sustainable feedstock into nutraceuticals, medicines, and essential chemicals. The company’s proprietary exozyme platform offers a scalable alternative to traditional petrochemical and cell-based production methods, with technology validated through publications in Nature Communications and Nature Chemical Biology. eXoZymes is led by an experienced management team including Michael Heltzen, CEO; Damien Perriman, CCO; Dr. Tyler Korman, CSO and Co-founder; Dr. Paul Opgenorth, VP of Development and Co-founder; Fouad Nawaz, VP of Finance; Dr. Zachary Karl, VP of Business Development; Lasse H. Görlitz, VP of Communications; and Amy Lunzer, Chief of Staff. To learn more about eXoZymes Inc., visit https://exozymes.com. For investor inquiries, visit https://exozymes.com/investor. Disclosure: David Shapiro, CEO of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted EXOZ stock, in line with B2i Digital’s practice of investing alongside its Featured Companies. This post is not intended to solicit the sale of EXOZ or any security, and it is not intended to offer any opinion on EXOZ as an investment. Conduct your own research and consult with your own professional advisors prior to making any investment decisions. See the complete disclosure in the Risks and Disclosures section of https://b2idigital.com/disclaimer.

$EXOZ Inverse or derivative ETF exposure. Designed for tactical use. Decay risk applies.

$EXOZ Exozymes is a speculative biotech with limited disclosure. Commercial viability remains unclear. Price action is highly volatile.

$EXOZ capital raise soon? only a few months of cash runway left...

$EXOZ RSI: 26.69, MACD: -0.3637 Vol: 0.57, MA20: 10.81, MA50: 11.76 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

$EXOZ Recent NASDAQ Amplify interview https://exozymes.com/blog/nasdaq-interview-heltzen

$EXOZ NCT system performs even better at scale! Before the recent 100L pilot plant scaling, eXoZymes produced 4 grams in the lab from an assumed 1L bioreactor. Now at 100L, they are achieving 535 grams! 99% Reaction Conversion 90% Isolated Yield 99.6% Pharma-grade Purity https://exozymes.com/blog/nct-pilot-run-details

Los Angeles-based eXoZymes Inc. (NASDAQ: $EXOZ), a pioneer of AI-enhanced enzymes that transform sustainable feedstock into nutraceuticals and new medicines, reported detailed downstream performance results from its recently completed 100-liter pilot production run of N-trans-caffeoyltyramine (NCT). eXoZymes Inc. is a B2i Digital Featured Company. See their full profile at https://b2idigital.com/exozymes-1. The company reports that the pilot run achieved approximately 99% reaction conversion, 91% process recovery, and a 90% isolated yield, resulting in 535 grams of isolated NCT at 99.6% pharma-grade purity. The production was executed by external partner Cayman Chemical, marking the first time the exozyme-based biomanufacturing process has been run end-to-end by an external partner, demonstrating protocol transferability and operational robustness. Co-founder of eXoZymes and VP of Development, Paul Opgenorth, PhD, noted: “What makes this initial NCT pilot run profound is how counter to conventional experience these results are. In most biological systems, performance typically degrades as you scale - reactions become harder to control, yields drop, and variability increases. With our AI-enhanced enzymes - exozymes - we see the opposite trend. At very small laboratory scale, where cell-free reactions are usually developed and optimized, performance can actually be the weakest. It improves at the one-liter scale, and this scaled run at 100 liters further reinforces that the system benefits from operating at larger volumes. Seeing that behavior carry through to high recovery, isolated yield, and pharma-grade purity supports that exozymes represent a fundamentally different and more scalable biomanufacturing paradigm compared to existing approaches.” Read the full news release at: https://exozymes.com/blog/nct-pilot-run-details eXoZymes is a Los Angeles, California-based biotechnology company pioneering cell-free biomanufacturing through AI-engineered enzymes that transform sustainable feedstock into nutraceuticals, medicines, and essential chemicals. The company’s proprietary exozyme platform offers a scalable alternative to traditional petrochemical processes, with technology validated through publications in Nature Communications and Nature Chemical Biology. To learn more about eXoZymes Inc., visit https://exozymes.com. For investor inquiries, visit https://exozymes.com/investor. Disclosure: David Shapiro, CEO of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted EXOZ stock, in line with B2i Digital’s practice of investing alongside its Featured Companies. This post is not intended to solicit the sale of EXOZ or any security, and it is not intended to offer any opinion on EXOZ as an investment. Conduct your own research and consult with your own professional advisors prior to making any investment decisions. See the complete disclosure in the Risks and Disclosures section of https://b2idigital.com/disclaimer.

$EXOZ 5 million preferred share offering. Poision pill? https://investorshub.advfn.com/stock-market/NASDAQ/exozymes-EXOZ/stock-news/97634377/form-s-3-registration-statement-under-securities

$EXOZ “We need the last and most important thing: commercial scale” eXoZymes is planning on scaling their technology in Q3 (July-September) this year! One of the final major derisking events for their platform

$EXOZ A must watch for those interested in eXoZymes! Three of the company’s heavy hitters sit down and discuss the events of 2025 as well as the MASSIVE opportunities in 2026 and beyond https://exozymes.twentythree.com/secret/120191657/81412a44701bd80b4e8b55c7eb00d485?autoPlay=1&some&utm_campaign=209775304-Heltzen%27s%20Video%20Highlights&utm_source=twitter&utm_medium=social

$EXOZ RSI: 7.83, MACD: -0.9061 Vol: 1.59, MA20: 13.25, MA50: 13.92 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

$EXOZ RSI: 32.61, MACD: -0.7854 Vol: 1.52, MA20: 13.69, MA50: 13.98 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

In a recent International Business Times article, eXoZymes (Nasdaq: $EXOZ ) addressed one of biotech’s persistent frustrations: why promising molecules discovered in the lab so rarely make it to commercial scale. eXoZymes Inc. is a B2i Digital Featured Company. See their full profile at https://b2idigital.com/exozymes-1. The article examines the track record of cell-based synthetic biology approaches, which have often underdelivered on their promise. Living cells, it turns out, resist being repurposed as factories. They produce only what benefits them, in the amounts they need, and scaling production from lab bench to industrial bioreactor has proven stubbornly difficult. As described in the article, eXoZymes takes a different approach: using AI to engineer enzymes that work outside of cells entirely, in controlled bioreactors where temperature, pH, and other variables can be optimized for maximum yield. CEO Michael Heltzen framed the challenge this way: “Cells weren’t built to manufacture what we need, and they fight us every step of the way as they only want to make chemicals they themselves benefit from and only at the amount they need it. Using AI-engineered eXoZymes, we flip the model, as there are no living cells in our biosolutions.” According to the article, the company reports feedstock-to-product conversion efficiency exceeding 90 percent. Read the complete article: https://www.ibtimes.com/ai-meets-enzymes-exozymes-enables-high-yield-production-compounds-previously-impossible-make-3792509 eXoZymes is a Los Angeles, California-based biotechnology company pioneering cell-free biomanufacturing through AI-engineered enzymes that transform sustainable feedstock into nutraceuticals, medicines, and essential chemicals. The company’s proprietary exozyme platform offers a scalable alternative to traditional petrochemical processes, with technology validated through publications in Nature Communications and Nature Chemical Biology. eXoZymes is led by an experienced management team including Michael Heltzen, CEO; Damien Perriman, CCO; Dr. Tyler Korman, CSO and Co-founder; Dr. Paul Opgenorth, VP of Development and Co-founder; Fouad Nawaz, VP of Finance; Dr. Zachary Karl, Ph.D., VP of Business Development; Lasse H. Görlitz, VP of Communications; and Amy Lunzer, Chief of Staff. To learn more about eXoZymes Inc., visit https://exozymes.com. For investor inquiries, visit https://exozymes.com/investor. Disclosure: David Shapiro, CEO of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted EXOZ stock, in line with B2i Digital’s practice of investing alongside its Featured Companies. This post is not intended to solicit the sale of EXOZ or any security, and it is not intended to offer any opinion on EXOZ as an investment. Conduct your own research and consult with your own professional advisors prior to making any investment decisions. See the complete disclosure in the Risks and Disclosures section of https://b2idigital.com/disclaimer.

$EXOZ This is a pump and dump. Employees should abandon stock into year end

$EXOZ A reminder to all the new followers that we have set up a eXoZymes discord group Link in the posts comments

$DNA $EXOZ yup, everyone should gather around and listen to your wisdom so in 9 months we all can end up in the -51% in the red. Should change your nick to horse sh#t and your opinion as horse sh$T report.